Market news

VIENNA, Va., September 15, 2026--CEL-SCI invited to deliver keynote address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology.

VIENNA, Va., August 17, 2026--CEL-SCI reported financial results for three months ended June 30, 2026, as well as key recent corporate and clinical developments for Multikine.

VIENNA, Va., August 04, 2026--CEL-SCI study published in peer-reviewed Oral Oncology supports Multikine's biomarker strategy and potential overall survival benefit.

VIENNA, Va., July 30, 2026--Leading oncology journal accepts for publication new CEL-SCI Multikine Phase 3 data.

VIENNA, Va., July 13, 2026--CEL-SCI to launch FDA Registration-Enabling Phase 3 Confirmatory Study to bring Multikine to Market for newly diagnosed head and neck cancer.